ArticleFrontiers in medicine2021
Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Acute exacerbation in fibrotic interstitial lung disease: an international working group report.American journal of respiratory and critical care medicine · 2026Review
- Korean Clinical Practice Guidelines for Interstitial Lung Disease: Part 2. Idiopathic Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026Article
- Article
- Association of Pulse Dose Corticosteroids With Outcomes Among Patients With Acute Exacerbations of Idiopathic Pulmonary Fibrosis.CHEST pulmonary · 2025Article
- Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments.Journal of thoracic disease · 2024Review
- Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers.International journal of molecular sciences · 2023Review
- Acute exacerbation of interstitial lung disease in the intensive care unit: Principles of diagnostic evaluation and management.World journal of critical care medicine · 2023Review
- Comparing outcomes of ILD patients managed in specialised versus non-specialised centres.Respiratory research · 2022Article
- IPF-Acute Exacerbations: Advances and Future Perspectives.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 20 institutions in 19 countries.
Markus PolkeCenter for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Yasuhiro KondohDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Marlies WijsenbeekDepartment of Respiratory Medicine, Centre for Interstitial Lung Diseases and Sarcoidosis, Erasmus University Medical Centre, Rotterdam, Netherlands.
Vincent CottinNational Coordinating Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France.
Simon L F WalshImperial College, National Heart and Lung Institute, London, United Kingdom.
Harold R CollardDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Nazia ChaudhuriNorth West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, Wythenshawe, Manchester, United Kingdom.
Sergey AvdeevSechenov First Moscow State Medical University, Moscow, Russia.
Jürgen BehrMedizinische Klinik und Poliklinik V, LMU Klinikum, University of Munich, Munich, Germany.
Gregory CalligaroDivision of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Tamera J CorteRoyal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.
Kevin FlahertyDepartment of Medicine, University of Michigan, Ann Arbor, MI, United States.
Manuela Funke-ChambourDepartment of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Martin KolbDepartment of Medicine, Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Johannes KrisamInstitute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Toby M MaherHastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Maria Molina MolinaInstitut d'Investigació Biomèdica de Bellvitge (IDIBELL), University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Antonio MoraisDepartment of Pneumology, Faculdade de Medicina, Centro Hospitalar São João, Universidade do Porto, Porto, Portugal.
Catharina C MoorDepartment of Respiratory Medicine, Centre for Interstitial Lung Diseases and Sarcoidosis, Erasmus University Medical Centre, Rotterdam, Netherlands.
Julie MorissetDépartement de Médecine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Carlos PereiraLung Disease Department, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Silvia QuadrelliHospital Británico, Buenos Aires, Argentina.
Moises SelmanInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.
Argyrios TzouvelekisDepartment of First Academic Respiratory, Sotiria General Hospital for Thoracic Diseases, University of Athens, Athens, Greece.
Claudia ValenzuelaILD Unit, Pulmonology Department Hospital Universitario de La Princesa, Universidad Autonoma de Madrid, Madrid, Spain.
Carlo VancheriRegional Referral Centre for Rare Lung Diseases, A.O.U. Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy.
Vanesa Vicens-ZygmuntUnit of Interstitial Lung Diseases, Department of Pneumology, Pneumology Research Group, IDIBELL, L'Hospitalet de Llobregat, University Hospital of Bellvitge, Barcelona, Spain.
Julia WälscherCenter for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Wim WuytsUnit for Interstitial Lung Diseases, Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
Elisabeth BendstrupDepartment of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus C, Denmark.
Michael KreuterCenter for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Heidelberg University · DEImperial College London · GBInstitut d'Investigació Biomédica de Bellvitge · ESAarhus University Hospital · DKAzienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITCentre Hospitalier de l’Université de Montréal · CAHelios Salud · ARInstituto Nacional de Enfermedades Respiratorias · MXKU Leuven · BELudwig-Maximilians-Universität München · DEManchester University NHS Foundation Trust · GBMcMaster University · CARoyal Prince Alfred Hospital · AURuhrlandklinik · DESechenov University · RUSotiria General Hospital · GRTosei General Hospital · JPUniversidad Autónoma de Madrid · ESUniversidade do Porto · PTUniversidade Federal de São Paulo · BR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
acute exacerbationidiopathic pulmonary fibrosisnon-specialised ILD centrespulmonologistsquestionnairespecialised ILD centres
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.